Correlation Between Astellas Pharma and Bristol-Myers Squibb
Can any of the company-specific risk be diversified away by investing in both Astellas Pharma and Bristol-Myers Squibb at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Astellas Pharma and Bristol-Myers Squibb into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Astellas Pharma and Bristol Myers Squibb, you can compare the effects of market volatilities on Astellas Pharma and Bristol-Myers Squibb and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Astellas Pharma with a short position of Bristol-Myers Squibb. Check out your portfolio center. Please also check ongoing floating volatility patterns of Astellas Pharma and Bristol-Myers Squibb.
Diversification Opportunities for Astellas Pharma and Bristol-Myers Squibb
-0.38 | Correlation Coefficient |
Very good diversification
The 3 months correlation between Astellas and Bristol-Myers is -0.38. Overlapping area represents the amount of risk that can be diversified away by holding Astellas Pharma and Bristol Myers Squibb in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Bristol Myers Squibb and Astellas Pharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Astellas Pharma are associated (or correlated) with Bristol-Myers Squibb. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Bristol Myers Squibb has no effect on the direction of Astellas Pharma i.e., Astellas Pharma and Bristol-Myers Squibb go up and down completely randomly.
Pair Corralation between Astellas Pharma and Bristol-Myers Squibb
Assuming the 90 days horizon Astellas Pharma is expected to under-perform the Bristol-Myers Squibb. But the pink sheet apears to be less risky and, when comparing its historical volatility, Astellas Pharma is 3.83 times less risky than Bristol-Myers Squibb. The pink sheet trades about -0.05 of its potential returns per unit of risk. The Bristol Myers Squibb is currently generating about 0.0 of returns per unit of risk over similar time horizon. If you would invest 119,399 in Bristol Myers Squibb on November 9, 2024 and sell it today you would lose (21,599) from holding Bristol Myers Squibb or give up 18.09% of portfolio value over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Against |
| Strength | Insignificant |
| Accuracy | 23.94% |
| Values | Daily Returns |
Astellas Pharma vs. Bristol Myers Squibb
Performance |
| Timeline |
| Astellas Pharma |
| Bristol Myers Squibb |
Risk-Adjusted Performance
Weak
Weak | Strong |
Astellas Pharma and Bristol-Myers Squibb Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Astellas Pharma and Bristol-Myers Squibb
The main advantage of trading using opposite Astellas Pharma and Bristol-Myers Squibb positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Astellas Pharma position performs unexpectedly, Bristol-Myers Squibb can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Bristol-Myers Squibb will offset losses from the drop in Bristol-Myers Squibb's long position.| Astellas Pharma vs. Bayer AG | Astellas Pharma vs. Daiichi Sankyo | Astellas Pharma vs. AstraZeneca PLC | Astellas Pharma vs. Astellas Pharma |
| Bristol-Myers Squibb vs. Novartis AG | Bristol-Myers Squibb vs. Bayer AG | Bristol-Myers Squibb vs. Astellas Pharma | Bristol-Myers Squibb vs. Roche Holding AG |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Other Complementary Tools
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format |